Precision medicine in MASLD: Integrating genetics, multi-omics, and artificial intelligence for risk stratification and targeted therapy.
Identifying personalized liver disease subtypes could guide treatment decisions and improve long-term outcomes for patients.
This PubMed-indexed study examined metabolic dysfunction-associated steatotic liver disease (MASLD), formerly termed nonalcoholic fatty liver disease (NAFLD), encompasses a heterogeneous clinical spectrum ranging from isolated hepatic steatosis to metabolic. The abstract reports we outline the remaining challenges and research priorities needed to integrate precision hepatology into routine care, highlighting the identification of clinically actionable MASLD subtypes and the equitable translation of findings into improved long-term.
What the study was
- Study design
- Narrative Review
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Clinica chimica acta; international journal of clinical chemistry
Why it surfaced
Conservative triage based on the PubMed abstract: narrative review with direct watchlist relevance; score reflects metadata and abstract-level evidence only.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.